Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

BMC Gastroenterology

Table 2 Treatment regimen^a

Study	Patients	Albumin dose (g)	Vasoconstrictor		Treatment duration (d)
Randomized			Type	Dose (mg)
Alessandria et al., 2007 [18]	5	350	terlipressin	55	7.6
	4	406	noradrenaline	188	7.2
Martín-Llahí et al., 2008 [19]	17	190	terlipressin	66	7.0
Neri et al., 2008 [20]	26	836	terlipressin	36	19.0
Sanyal et al., 2008 [21]	56	304	terlipressin	28	6.3
Sharma et al., 2008 [22]	20	243	terlipressin	47	8.1
	20	234	noradrenaline	187	7.8
Silawat et al., 2011 [27]	30	88	terlipressin	10	7.0
Singh et al., 2012 [29]	23	156	terlipressin	24	7.8
	23	186	noradrenaline	132	9.3
Tavakkoli et al., 2012 [30]	9	720	midodrine/octreotide	270/5.4	18.0
	6	720	noradrenaline	146	18.0
Prospective
Angeli et al., 1999 [13]	5	300	midodrine/octreotide	630/9.6	20.0
Uriz et al., 2000 [14]	6	358	terlipressin	48	10.6
Mulkay et al., 2001 [15]	12	200	terlipressin	72	26.0
Wong et al., 2004 [17]	14	700	midodrine/octreotide	35/8.4	14.0
Muñoz et al., 2009 [23]	13	592	terlipressin	41	9.6
Rivero et al., 2010 [26]	41	250	terlipressin	63	7.0
Salerno et al., 2011 [1]	40	235	terlipressin	63	8.7
	24	235	midodrine/octreotide	207/2.8	8.7
Narahara et al., 2012 [28]	8	162	terlipressin	18	6.3
Moreau et al., 2002 [16]	99	433	terlipressin	36	11.4
Skagen et al., 2009 [24]	49	368	midodrine/octreotide	222/3.6	8.4
von Kalckreuth et al., 2009 [25]	24	193	terlipressin	27	7.1

ISSN: 1471-230X